# Natco Pharma: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Natco Pharma Limited · NSE: NATCOPHARM · BSE: 524816 · Sector: Healthcare

Updated for Q2 FY27 · checked 16 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/natco-pharma. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Natco Pharma: how the business works", with the page URL.

## In short

Partner drug companies, distributors and other buyers in India and more than 50 export countries, most of all the US, pay Natco Pharma for its medicines and drug ingredients; running costs, materials and staff take most of the money, and ₹32.1 of every ₹100 that came in was left as profit in FY26.

- One customer that Natco does not name gave 41.4% of FY26 revenue, down from 60.6% in FY25.
- Quarterly revenue fell from ₹1,363 crore in Q2 FY26 to ₹647 crore in Q3 FY26; management said on 14 Nov 2025 that the Dec 2025 quarter would be the first without substantial sales of generic Revlimid (lenalidomide).

## Key facts

**What does Natco Pharma do?**

Natco Pharma Ltd is a Hyderabad drug maker, incorporated in 1981, that develops complex generic medicines for the US with partner companies, sells cancer and other medicines in India, and makes drug ingredients (APIs) and crop-protection products. Natco Pharma's FY26 revenue from operations was ₹4,078 crore. [S1, S7, S19]

**How does Natco Pharma make money?**

By Natco Pharma's own business-line figures for FY26, formulation exports (including profit share and licence income from partners and sales of overseas subsidiaries) brought in ₹3,235 crore, domestic formulations ₹441 crore, APIs ₹235 crore and crop health products ₹138 crore, out of total revenue of ₹4,376 crore including other income. [S20]

**Who are Natco Pharma's customers?**

In FY26, customers in the US gave Natco Pharma 58.4% of its revenue from operations, India 16.9% and other countries 24.7%. One customer that Natco Pharma does not name gave ₹1,687 crore, or 41.4% of FY26 revenue, against 60.6% of FY25 revenue. [S1]

**How big is Natco Pharma?**

Natco Pharma's FY26 revenue from operations was ₹4,078 crore and its profit for shareholders ₹1,419 crore, against ₹4,430 crore and ₹1,885 crore in FY25. In Q2 FY27 (July to September 2026) Natco Pharma's revenue from operations was ₹967 crore and profit for shareholders ₹203 crore. [S1, S7, S65]

**Who owns Natco Pharma?**

On 23 Oct 2026, after its rights issue, Natco Pharma's promoter group, which includes Chairman and Managing Director V C Nannapaneni, held 46.22% of the shares, foreign institutions 15.36%, Indian institutions 10.82% (mutual funds 7.01%) and other shareholders 27.60%. [S25]

**What is Natco Pharma's stake in Adcock Ingram?**

Natco Pharma owns 49% of Adcock Ingram, a South African medicine maker: it bought 35.75% in Nov 2025 and 13.25% more in Jul 2026. Natco Pharma's share of Adcock Ingram's profit was ₹84.3 crore in Q1 FY27 and ₹29.2 crore in Q2 FY27, 14.4% of its ₹203 crore Q2 FY27 profit for shareholders (Cityfort calculation). [S43, S45, S6, S65]

**Why did Natco Pharma's revenue fall?**

Natco Pharma's revenue from operations fell to ₹4,078 crore in FY26 from ₹4,430 crore in FY25, and was ₹967 crore in Q2 FY27 against ₹1,363 crore in Q2 FY26. Natco Pharma said in its Q2 FY27 results release that the fall was largely due to lower revenue from lenalidomide, its generic version of the US cancer medicine Revlimid. [S7, S65, S9, S66]

**What was Natco Pharma's 2026 rights issue?**

Natco Pharma allotted 17,058,082 new shares at ₹750 each to existing shareholders on 23 Oct 2026, raising ₹1,279 crore; its Letter of Offer sets aside ₹811 crore of the net proceeds to repay borrowings. Natco Pharma's share count rose from 179,109,870 to 196,167,952. [S40, S41, S39]

**What dividend does Natco Pharma pay?**

Natco Pharma paid interim dividends of ₹5.00 a share for FY26 and ₹6.00 a share for FY25, and for FY27 declared interim dividends of ₹1.50 a share on 14 Aug 2026 and ₹1.25 a share on 13 Nov 2026 (record date 19 Nov 2026). [S1, S2, S17, S66]

## What does Natco Pharma sell?

Natco makes medicines. Its biggest business develops generic copies of complex US medicines, often by challenging the brand's patents, and sells them through partner companies. In India it sells its own brands, including more than 40 cancer brands. It also sells drug ingredients and crop-protection products, and owns 49% of South African medicine maker Adcock Ingram.

- **Generic medicines for the US and other export markets:** Formulation exports, including profit share and licence income from partners and sales of overseas subsidiaries, brought in ₹3,235 crore in FY26, 73.9% of total revenue. Natco aims at products that are hard to make and have few competitors, and shares patent litigation and selling with partner companies. Its biggest product was lenalidomide, a generic of the US cancer medicine Revlimid (multiple myeloma), launched in the US in 2022. [S20, S19, S38]
- **Branded medicines in India:** Domestic formulations brought in ₹441 crore in FY26. Natco has about 900 sales staff, more than 1,000 distributors and more than 40 cancer brands, 10 of them with sales above ₹10 crore. In Mar 2026 it launched generic semaglutide, a type 2 diabetes injection, in multi-dose vials from ₹1,290 a month. [S20, S19, S47]
- **Drug ingredients (APIs):** Active pharmaceutical ingredients, the chemical that makes a medicine work, sold to other drug makers: ₹235 crore in FY26. [S20]
- **Crop Health Sciences:** Crop-protection products for farmers: ₹138 crore of revenue in FY26, with a segment loss of ₹19.8 crore. The board approved on 24 Mar 2026 a plan to demerge this business into Natco Crop Health Sciences Ltd; it has not taken effect. [S20, S1, S46]
- **49% of Adcock Ingram:** A South African medicine maker. Natco bought 35.75% for about ₹2,000 crore (completed Nov 2025) and 13.25% more for ZAR 1,814.7 million, about ₹1,069 crore (completed 14 Jul 2026). Natco does not count Adcock's sales as its revenue; it books its share of Adcock's profit. [S42, S43, S44, S45]

## Who pays Natco Pharma?

- **Buyers in the US (58.4% of revenue):** Natco sells its complex US generics through partner companies, and its export revenue includes profit share and licence income from partners. Revenue from the US was ₹2,381 crore in FY26, against ₹3,149 crore in FY25. [S1, S19, S20]
- **Buyers in India (16.9% of revenue):** Buyers of Natco's medicines in India, reached through more than 1,000 distributors, and Indian buyers of its drug ingredients and crop products: ₹691 crore in FY26. [S1, S19]
- **Buyers in other countries (24.7% of revenue):** Customers in more than 50 countries, including those of Natco's subsidiaries in Brazil (₹288 crore of revenue in FY26) and Canada: ₹1,006 crore in FY26. [S1, S38]
- **Customer concentration:** largest customer 41.4% of revenue. One customer that Natco does not name gave ₹1,687 crore, or 41.4% of FY26 revenue, against ₹2,686 crore (60.6%) in FY25 and 45.7% in FY24. That customer owed Natco ₹20.5 crore on 31 Mar 2026, against ₹731 crore a year earlier. ICRA says a few molecules drive the US business, particularly generic Revlimid in FY2025 and H1 FY2026. [S1, S2, S3, S38]

## Where the money went (FY26)

1. In FY26 Natco's medicines, ingredients and crop products brought in ₹4,078 crore of revenue.
2. Other income added ₹298 crore, and Natco's share of Adcock Ingram's profit added ₹46.6 crore.
3. Materials and goods bought took ₹691 crore, staff ₹687 crore and other running costs ₹1,264 crore.
4. Depreciation took ₹207 crore and interest ₹36.7 crore; income tax was ₹119 crore after a one-time ₹115 crore credit.
5. What was left for Natco's shareholders was ₹1,419 crore of profit.

Sources: S7, S1, S20.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 1,944.8 | 263.5 | 13.5% | 170 | 8.7% | 9.32 | 46.5 | 242.7 | −196.2 | S16, S5, S4 |
| FY23 | 2,707.1 | 935.6 | 34.6% | 715.3 | 26.4% | 39.18 | 849.1 | 205.6 | 643.5 | S15, S4 |
| FY24 | 3,998.8 | 1,751.4 | 43.8% | 1,388.3 | 34.7% | 77.34 | 1,211.6 | 358.7 | 852.9 | S14, S3 |
| FY25 | 4,429.5 | 2,196 | 49.6% | 1,885.4 | 42.6% | 105.26 | 1,696.8 | 511.6 | 1,185.2 | S11, S2, S1 |
| FY26 | 4,078.3 | 1,436.5 | 35.2% | 1,418.5 | 34.8% | 79.2 | 1,768.3 | 391.1 | 1,377.2 | S7, S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 31 Mar 2026, ₹ crore)

On 31 Mar 2026 Natco's cash and liquid investments were ₹1,423 crore more than its borrowings (Cityfort calculation from the FY26 annual report); management said net cash was around ₹1,400 crore in Aug 2026, after paying for the second Adcock stake. [S1, S7, S39, S41, S21]

| Item | Value |
| --- | --- |
| Total debt | 706.4 |
| Cash and investments | 2,129.1 |
| Net debt (debt minus cash) | −1,422.7 |
| Net worth (shareholders' money) | 9,221.1 |
| Debt to equity (times) | 0.08 |

- Borrowings rose from ₹273 crore on 31 Mar 2025 to ₹706 crore on 31 Mar 2026, including a ₹400 crore term loan, and were ₹954 crore on 31 Aug 2026 (rights issue Letter of Offer). Lease liabilities (₹7.5 crore on 31 Mar 2026) are not included.
- The Oct 2026 rights issue raised ₹1,279 crore after these dates; the Letter of Offer sets aside ₹811 crore of the net proceeds to repay borrowings, ₹110 crore for research and ₹339 crore for acquisitions not yet identified and general purposes.
- Cash and liquid investments = cash, other bank balances and current investments; debt to equity = borrowings ÷ net worth (Cityfort calculations). Deposits with financial institutions held under other financial assets are not counted.
- Natco's investment in Adcock Ingram was carried at ₹2,276 crore on 31 Mar 2026, of total assets of ₹11,074 crore.

## Who owns Natco Pharma? (shareholding, 23 Oct 2026 (after the rights issue))

| Holder | % of shares |
| --- | --- |
| Promoters | 46.22% |
| Promoter shares pledged (% of promoter shares) | 0.94% |
| Foreign institutions (FII) | 15.36% |
| Indian institutions (DII) | 10.82% |
| Public | 27.6% |

Sources: S37, S36, S35, S34, S33, S32, S31, S30, S29, S28, S27, S26, S25.

## What could go wrong

### One customer, a few products

One customer that Natco does not name gave 41.4% of FY26 revenue and 60.6% of FY25 revenue. ICRA says disruption in any key product can cause large swings in revenue and margins. [S1, S2, S38]

What to watch: The customer-concentration note in the FY27 annual report (41.4% in FY26).

### Revenue after lenalidomide

Revenue from operations was ₹1,329 crore in Q1 FY26 and ₹1,363 crore in Q2 FY26, then between ₹647 crore and ₹739 crore in each of the next three quarters. It was ₹967 crore in Q2 FY27. Management said on 14 Aug 2026 that lenalidomide revenue was negligible in Q1 FY27. Natco said the Q2 FY27 fall from a year earlier was largely due to lower lenalidomide revenue. [S10, S9, S8, S7, S6, S65, S66, S21]

What to watch: Q3 FY27 revenue, against ₹967 crore in Q2 FY27 and ₹647 crore in Q3 FY26.

### Profit leans on Adcock Ingram

Natco's ₹84.3 crore share of Adcock's profit was about 41% of Q1 FY27 profit for shareholders. Management said a strong flu season in South Africa lifted that quarter and that the exchange rate affects Adcock's figures. In Q2 FY27 the share was ₹29.2 crore, 14.4% of profit (Cityfort calculation). Adcock reported ₹80.5 crore of Q2 profit; Natco said its share is after a provisional purchase price adjustment. [S6, S65, S66, S21, S22, S45]

What to watch: Share of associate profit each quarter at the 49% stake (₹29.2 crore in Q2 FY27, ₹84.3 crore in Q1 FY27).

### Promoter shares pledged

850,000 shares of Chairman V C Nannapaneni were pledged in the 23 Oct 2026 filing, 0.94% of the promoter holding, the first pledge in the filings since Dec 2023. If pledged shares are sold to repay a loan, the promoter stake falls. The filings checked do not give a reason. [S25, S37]

What to watch: Pledged shares in the Dec 2026 shareholding filing (850,000 on 23 Oct 2026).

### US FDA inspections

Plants that supply the US must pass US FDA inspections. The Visakhapatnam formulation plant got a Form 483 with 4 observations in Aug 2026; the Kothur plant was under a warning letter from FY2024 until Sep 2025, ICRA says. [S53, S38]

What to watch: The FDA's classification of the Aug 2026 Visakhapatnam inspection.

### Patent fights

Natco's model depends on challenging patents, and ICRA says it monitors any adverse outcome of such litigation. In India, Roche's risdiplam suit against Natco goes to trial after the Supreme Court dismissed Roche's petition on interim relief in Oct 2025. [S38, S54]

What to watch: Court rulings and settlements announced by Natco or its partners.

### Acquisitions with the new money

The rights issue sets aside ₹339 crore for acquisitions not yet identified and general purposes. Management said in Aug 2026 that it was looking at acquisition opportunities, after spending about ₹3,000 crore, mostly on Adcock. [S39, S21, S65]

What to watch: Any acquisition announced, and borrowings after repayment (₹1,027 crore on 30 Sep 2026, before the rights money came in).

### Price competition

ICRA notes competition-led price pressure in Natco's Indian and US markets. Management called the Indian semaglutide market super competitive in May 2026. [S38, S22, S19, S67]

What to watch: Domestic formulations revenue each quarter (₹146 crore in Q2 FY27, ₹136 crore in Q1 FY27).

## What to watch

Next: Q3 FY27 results (expected), 12 Feb 2027 (expected).

- **Q3 FY27 results, expected about mid-Feb 2027:** Natco has not announced the date; Q3 FY26 results came on 12 Feb 2026. The 31 Dec 2026 balance sheet will be the first after the ₹1,279 crore rights issue of Oct 2026.
- **Sales and profit against guidance:** Management said on 14 Aug 2026 it expects FY27 gross sales of ₹3,300–3,400 crore and profit of about ₹750 crore; H1 FY27 total revenue was ₹1,814 crore and profit ₹409 crore.
- **Promoter pledge and holding:** On 23 Oct 2026 promoters held 46.22% and 850,000 of their shares were pledged; the Dec 2026 shareholding filing will show any change.

## Sources

- S1: Annual Report 2025-26 (FY26). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_31441_NATCOPHARM_2025_2026_A_20000089_04092026200058.pdf (published 4 Sep 2026)
- S2: Annual Report 2024-25 (FY25). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_27894_NATCOPHARM_2024_2025_A_14237439_29082025180426.pdf (published 29 Aug 2025)
- S3: Annual Report 2023-24 (FY24). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_25699_NATCOPHARM_2023_2024_04092024175611.pdf (published 4 Sep 2024)
- S4: Annual Report 2022-23 (FY23; NSE zip). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_23445_NATCOPHARM_2022_2023_04092023203236_09042023210011.zip (published 4 Sep 2023)
- S5: Annual Report 2021-22 (FY22; NSE zip). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_21076_NATCOPHARM_2021_2022_02092022150055_09022022160013.zip (published 2 Sep 2022)
- S6: Q1 FY27 consolidated results (XBRL, Integrated Filing). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1714414_14082026040441_WEB.xml (published 14 Aug 2026)
- S7: Q4 FY26 and FY26 consolidated results (XBRL, Integrated Filing). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1676129_29052026052020_WEB.xml (published 29 May 2026)
- S8: Q3 FY26 consolidated results (XBRL, Integrated Filing). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1624147_12022026044856_WEB.xml (published 12 Feb 2026)
- S9: Q2 FY26 consolidated results (XBRL, Integrated Filing). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1574886_14112025035301_WEB.xml (published 14 Nov 2025)
- S10: Q1 FY26 consolidated results (XBRL, Integrated Filing). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1509409_12082025033516_WEB.xml (published 12 Aug 2025)
- S11: Q4 FY25 and FY25 consolidated results (XBRL, Integrated Filing). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1454901_28052025055526_WEB.xml (published 28 May 2025)
- S12: Q3 FY25 consolidated results (XBRL). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_119898_1379856_12022025044609.xml (published 12 Feb 2025)
- S13: Q2 FY25 consolidated results (XBRL). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_115097_1305666_12112024034230.xml (published 12 Nov 2024)
- S14: Q4 FY24 and FY24 consolidated results (XBRL). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_107331_1140116_27052024050639.xml (published 27 May 2024)
- S15: Q4 FY23 and FY23 consolidated results (XBRL). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_93383_857041_29052023100647.xml (published 29 May 2023)
- S16: Q4 FY22 and FY22 consolidated results (XBRL). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_86574_668908_31052022120431_WEB.xml (published 31 May 2022)
- S17: Q1 FY27 board outcome and press release (results, interim dividend, fund-raise approval). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_14082026140905_BMOutcome_14082026.pdf (published 14 Aug 2026)
- S18: Earnings presentation Q1 FY27. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_14082026173614_IP_14082026.pdf (published 14 Aug 2026)
- S19: Investor presentation August 2026. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_19082026090147_InvestorPresentation19082026.pdf (published 19 Aug 2026)
- S20: Earnings presentation Q4 FY26 and FY26. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_29052026153007_InvestorPresentation_29052026.pdf (published 29 May 2026)
- S21: Q1 FY27 earnings call transcript (call 14 Aug 2026). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_18082026123626_Q1EarningscallTranscript.pdf (published 18 Aug 2026)
- S22: Q4 FY26 earnings call transcript (call 29 May 2026). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_04062026145952_EarningsCallTranscript_29052026.pdf (published 4 Jun 2026)
- S23: Q3 FY26 earnings call transcript (call 12 Feb 2026). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_18022026153458_Q3EarningscallTranscript.pdf (published 18 Feb 2026)
- S24: Q2 FY26 earnings call transcript (call 14 Nov 2025). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_20112025163532_Q2EarningscallTranscript.pdf (published 20 Nov 2025)
- S25: Shareholding pattern as of 23 Oct 2026 (after rights allotment). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1750875_01112026105327_WEB.xml (published 1 Nov 2026)
- S26: Shareholding pattern 2026-09-30. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1740079_16102026045222_WEB.xml (published 16 Oct 2026)
- S27: Shareholding pattern 2026-06-30. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1689944_09072026054425_WEB.xml (published 9 Jul 2026)
- S28: Shareholding pattern 2026-03-31. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1647709_09042026102912_WEB.xml (published 9 Apr 2026)
- S29: Shareholding pattern 2025-12-31. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1603978_19012026020157_WEB.xml (published 19 Jan 2026)
- S30: Shareholding pattern 2025-09-30. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1543722_09102025062609_WEB.xml (published 9 Oct 2025)
- S31: Shareholding pattern 2025-06-30. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1482950_15072025022733_WEB.xml (published 15 Jul 2025)
- S32: Shareholding pattern 2025-03-31. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_197335_1415362_16042025104507_WEB.xml (published 16 Apr 2025)
- S33: Shareholding pattern 2024-12-31. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_193987_1398143_20032025025533_WEB.xml (published 8 Jan 2025)
- S34: Shareholding pattern 2024-09-30. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_191820_1267923_14102024024421_WEB.xml (published 14 Oct 2024)
- S35: Shareholding pattern 2024-06-30. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_188978_1178430_10072024044528_WEB.xml (published 10 Jul 2024)
- S36: Shareholding pattern 2024-03-31. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_186509_1089824_12042024050213_WEB.xml (published 12 Apr 2024)
- S37: Shareholding pattern 2023-12-31. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_183362_1010369_08012024031312_WEB.xml (published 8 Jan 2024)
- S38: ICRA rationale "Natco Pharma Limited: Ratings reaffirmed" (28 Nov 2025), with rating letter, filed with exchanges. ICRA Limited (via Natco filing on NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_29112025095113_Cresit_Ratings_SE_Intimation_29112025.pdf (published 29 Nov 2025)
- S39: Letter of Offer, rights issue 2026 (filed with Fund Raising Committee outcome 28 Sep 2026). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_28092026205152_Outcome_FundRaising_Committee_Meeting_28092026.pdf (published 28 Sep 2026)
- S40: Board outcome: rights issue terms (price, ratio, record date). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_25092026111109_OutcomeofBM_25092026.pdf (published 25 Sep 2026)
- S41: Allotment of 17,058,082 rights equity shares. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_23102026210658_Outcome_of_FRC23102026.pdf (published 23 Oct 2026)
- S42: Board approval to acquire 35.75% of Adcock Ingram Holdings. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_23072025160328_Reg30intimation23072025.pdf (published 23 Jul 2025)
- S43: Adcock Ingram completes delisting from JSE; Natco acquires 35.75% stake. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_12112025150205_PressRelease_12112025.pdf (published 12 Nov 2025)
- S44: Board approval to raise Adcock Ingram stake from 35.75% to 49%. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_08072026120058_BMOutcome08072026.pdf (published 8 Jul 2026)
- S45: Natco completes acquisition of additional 13.25% stake in Adcock Ingram. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_14072026115438_PressRelease_14072026.pdf (published 14 Jul 2026)
- S46: Board approval of scheme to demerge the agrochemicals business into Natco Crop Health Sciences Ltd. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_24032026171413_OutcomeOfBoardMeeting_24032026.pdf (published 24 Mar 2026)
- S47: Launch of generic semaglutide multi-dose vials in India. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_20032026093010_PressReleasee_20032026.pdf (published 20 Mar 2026)
- S48: US FDA inspection, Kothur pharma division: Form 483 with 7 observations. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_19062025181823_SEupdate.pdf (published 19 Jun 2025)
- S49: US FDA EIR for Kothur: Voluntary Action Indicated. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_18092025094438_DisclosuretoSE18092025.pdf (published 18 Sep 2025)
- S50: US FDA EIR for Mekaguda API unit (1 observation, VAI). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_24072025135959_SEupdate24072025.pdf (published 24 Jul 2025)
- S51: US FDA inspection, Manali (Chennai) API unit: Form 483 with 7 observations. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_21112025161530_PressRelese_21112025.pdf (published 21 Nov 2025)
- S52: US FDA EIR for Manali API unit: Voluntary Action Indicated. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_13022026091808_PressRelease13022026.pdf (published 13 Feb 2026)
- S53: US FDA inspection, Visakhapatnam FDF unit: Form 483 with 4 observations. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_21082026172327_DisclosuretoSE21082026.pdf (published 21 Aug 2026)
- S54: Legal update: Supreme Court dismisses Roche petition in Risdiplam suit. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_17102025170831_PressRelease_17102025.pdf (published 17 Oct 2025)
- S55: Regulatory update: Mylan and Novo Nordisk settle US generic Ozempic patent litigation (Natco partnered with Mylan). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_07102024084231_RegulatoryUpdate07102024.pdf (published 7 Oct 2024)
- S56: NPPA demand notice (Rs 4.92 crore, alleged overcharging, Apr-Nov 2023). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_14052026161616_DisclosuretoSE14052026.pdf (published 14 May 2026)
- S57: Appointment of Amit Parekh as CFO from 13 Feb 2026. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_12022026154428_Regulation30Disclosure.pdf (published 12 Feb 2026)
- S58: Investment in eGenesis, Inc.. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_25082026121818_PressRelease_eGenesis_25082026.pdf (published 25 Aug 2026)
- S59: eGenesis investment raised to US$16.70 million. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_28092026145628_LODR_Disclosure_eGenesis28092026.pdf (published 28 Sep 2026)
- S60: Prior intimation: board meeting 13 Nov 2026 for Q2 FY27 results and dividend (XBRL). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_1299_WebXMLFile_20261029_171627555.xml (published 29 Oct 2026)
- S61: Q2 FY27 earnings call intimation (13 Nov 2026, 4 pm IST). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_06112026162736_ConcallIntimationtoSE06112026.pdf (published 6 Nov 2026)
- S62: NSE CM bhavcopy 11 Nov 2026 (NATCOPHARM row). National Stock Exchange of India. https://nsearchives.nseindia.com/products/content/sec_bhavdata_full_11112026.csv (published 11 Nov 2026)
- S63: NSE equity list (NATCOPHARM: listed 27 Dec 1995, ISIN INE987B01026, face value Rs 2). National Stock Exchange of India. https://nsearchives.nseindia.com/content/equities/EQUITY_L.csv (published 12 Nov 2026)
- S64: Reply to NSE clarification: semaglutide partnership with Eris Lifesciences in ordinary course. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_25022026100135_NSEreply25022026.pdf (published 25 Feb 2026)
- S65: Q2 FY27 consolidated results (XBRL, Integrated Filing). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1757276_13112026032003_WEB.xml (published 13 Nov 2026)
- S66: Q2 FY27 board outcome and press release (results, second interim dividend). Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_13112026141002_Outcome_13112026.pdf (published 13 Nov 2026)
- S67: Earnings presentation Q2 FY27. Natco Pharma Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/NATCOPHARM_13112026155501_Q2FY27_EarningsPresentation.pdf (published 13 Nov 2026)
